Taiwan Expands Access to Flu Antivirals Amid Rising Cases

The government of Taiwan has announced an expansion of eligibility for government-funded influenza antiviral medications. Starting from January 20, 2024, until February 28, 2024, seven designated groups at higher risk for virus transmission will have access to these treatments. This decision by the Centers for Disease Control (CDC) comes as the flu is anticipated to enter an epidemic phase towards the end of January.

In a statement released yesterday, CDC Deputy Director-General Lin Min-cheng highlighted the urgency of the situation, noting that hospital visits for flu-like illnesses reached 82,161 during the last week of December, maintaining similar levels to the previous week. The CDC predicts that flu cases may peak around the upcoming Lunar New Year, which falls in mid-February.

The groups eligible for the antiviral medications include healthcare personnel, caregivers in nursing homes, childcare providers, students across various educational levels, and those living with individuals vulnerable to severe flu complications. Also included are workers in poultry and livestock farming, as well as people residing in high-density environments prone to outbreaks.

Lin emphasized that while the CDC typically broadens eligibility during epidemic periods, this proactive measure aims to mitigate the spread of the virus. He noted that recent data indicated that influenza remains the predominant respiratory virus in Taiwan, accounting for 43.8 percent of respiratory illness cases. This is significantly higher than adenoviruses and rhinoviruses, which accounted for 15.8 percent and 15.4 percent of cases, respectively.

Amid rising concerns, there have been reports of an increase in rhinovirus cases in China. While Taiwan has also experienced a slight uptick in rhinovirus infections, Lin reassured the public that these viruses have not surpassed flu cases in prevalence. The CDC continues to monitor changes in viral activity, especially as travel increases during the festive season.

The rhinovirus primarily affects the upper respiratory tract, leading to symptoms such as a runny nose and cough. These symptoms typically resolve within a week to ten days, and the health risks associated with rhinovirus are considerably lower than those posed by influenza. Lin stated, “It usually only causes inconvenience to people’s daily lives, but does not cause incapacity to work,” highlighting the stark differences between the two viruses.

In contrast, flu infections often result in widespread body aches and fatigue, with a higher risk of severe complications, particularly for the elderly and those with chronic health conditions. Chi Hsin, director of pediatrics at MacKay Memorial Hospital, noted common symptoms of rhinovirus infections, which can be categorized into three types: A, B, and C. He cautioned that rhinovirus C infections can exacerbate asthma or trigger allergic reactions, posing higher risks for children with existing respiratory conditions.

Furthermore, Chiu Cheng-hsun, deputy superintendent at Linkou Chang Gung Memorial Hospital, warned that individuals who are immunocompromised or have underlying health issues may face greater risks if infected with rhinovirus. He mentioned that ongoing observation is necessary to determine whether the increasing rhinovirus cases in China indicate potential mutations or increased co-infections.

As Taiwan prepares for the upcoming holiday season, public health officials remain vigilant in monitoring both flu and rhinovirus activity to safeguard public health.